Bioxytran Reports Encouraging CIDP Patient Response to PLICID

What Happened
On August 11, 2026, Bioxytran, Inc. (BIXT) announced via Form 8-K (Item 8.01) that it observed "encouraging clinical observations" in the first chronic inflammatory demyelinating polyneuropathy (CIDP) patient treated with PLICID. The company described PLICID as a novel galectin antagonist designed with artificial intelligence. The related press release was filed as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: August 11, 2026 (Form 8-K, Item 8.01).
• Press release titled: “Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID…” was filed as Exhibit 99.1.
• PLICID is characterized by the company as a novel galectin antagonist developed using artificial intelligence.
• Announcement concerns the first CIDP patient treated — described only as “encouraging clinical observations”; no new financial results or regulatory filings were reported in the 8‑K.

Why It Matters
This filing confirms Bioxytran has begun treating patients in its CIDP program and is reporting early clinical observations for PLICID, which is relevant to the company's clinical development progress. For investors, such clinical updates can influence perceptions of development momentum, but the company provided only preliminary observations in a press release (filed as an exhibit) rather than detailed efficacy or regulatory data. Investors should look for follow‑up data releases or formal clinical study updates for more substantive evidence of safety or efficacy.